Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial by Ruihao Huang, Xiaoqi Wang, Hongju Yan, Xu Tan, Yingying Ma, Maihong Wang, Xiao Han, Jia Liu, Li Gao, Lei Gao, Guangjun Jing, Cheng Zhang, Qin Wen, Xi Zhang

Subjects: “…CAR-NK…”
Get full text

<i>shp-2</i> gene knockout upregulates CAR-driven cytotoxicity of YT NK cells by V. G. Subrakova, S. V. Kulemzin, T. N. Belovezhets, A. N. Chikaev, N. A. Chikaev, O. A. Koval, A. A. Gorchakov, A. V. Taranin

Subjects: Get full text

Enhancement of anti‐sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2‐targeted CAR by Pui Yeng Lam, Natacha Omer, Josh K. M. Wong, Cui Tu, Louisa Alim, Gustavo R. Rossi, Maria Victorova, Hannah Tompkins, Cheng‐Yu Lin, Ahmed M. Mehdi, Amos Choo, Melissa R. Elliott, Elaina Coleborn, Jane Sun, Timothy Mercer, Orazio Vittorio, Lachlan J. Dobson, Alexander D. McLellan, Andrew Brooks, Zewen Kelvin Tuong, Seth W. Cheetham, Wayne Nicholls, Fernando Souza‐Fonseca‐Guimaraes

Subjects: “…CAR‐NK cell therapy…”
Get full text

Chimeric cytokine receptor TGF-β RⅡ/IL-21R improves CAR-NK cell function by reversing the immunosuppressive tumor microenvironment of gastric cancer by Yaojun Ren, Min Xue, Xinhui Hui, Xiuyu Liu, Muhammad Asad Farooq, Yiran Chen, Yuzhou Ji, Yixin Duan, Iqra Ajmal, Jie Yao, Wenzheng Jiang

Subjects: Get full text

Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy by Fatemeh Dehghan, Yekta Metanat, Mandana Askarizadeh, Ehsan Ahmadi, Vahid Moradi

Subjects: “…CAR-NK…”
Get full text